Chapter 17. Drug Delivery Systems Targeting Fungal Brain Diseases: Achievements, Challenges and Perspectives

$39.50

Cristina de Castro Spadari, Fernanda Wirth and Kelly Ishida
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

Part of the book: The Book of Fungal Pathogens

Abstract

Fungal infections have become a public health concern in recent decades. They can cause various pathological conditions, from superficial mycoses to invasive fungal infections (IFIs). Those that affect the central nervous system (CNS) are associated with significant morbidity and mortality. Available antifungal therapies are limited due to toxicity and resistance issues. Additionally, low drug delivery and subsequent bioavailability in the CNS impair some drugs’ efficacy since they must cross the blood-brain barrier (BBB) to achieve ideal concentrations in the brain tissues. This chapter addresses the currently available IFI treatments and discusses the potential use of drug delivery systems that carry antifungal agents across the BBB and target the CNS, consequently increasing drug bioavailability for treating fungal brain diseases.

Keywords: blood-brain barrier, central nervous system, meningitis, nanocarrier


References


[1] Góralska, K; Blaszkowska, J; Dzikowiec, M. Neuroinfections caused by fungi.
Infection, 2018 May 46, 443-459.
[2] Bloch, K C; Bailin, S S. Update on fungal infections of the central nervous system: emerging pathogens
and emerging diagnostics. Curr. Opin. Infect. Dis., 2019 Jun 32, 277-284.
[3] Geddes-McAlister, J; Shapiro, RS. New pathogens, new tricks: emerging, drug-resistant fungal
pathogens and future prospects for antifungal therapeutics. Ann. N Y Acad. Sci., 2019 Jan 1435, 57-78.
[4] Kantarcioglu, A S; Guarro, J; De Hoog, S; Apaydin, H; Kiraz, N. An updated comprehensive systematic
review of Cladophialophora bantiana and analysis of epidemiology, clinical characteristics, and
outcome of cerebral cases. Med. Mycol., 2017 Aug 55, 579-604.
[5] Gundamraj, S; Hasbun, R. The Use of Adjunctive Steroids in Central Nervous Infections. Front Cell
Infect. Microbiol., 2020 Nov 10, 1-13.
[6] Murthy, J M K; Sundaram, C. Neurologic aspects of infectious diseases/tropical neurology: Fungal
infections of the central nervous system. In: Biller J and Ferro J M, editors. Handbook of Clinical
Neurology: Neurologic Aspects of Systemic Disease Part III. Maywood, IL, USA: Elsevier; 2014; 1383-1401.
[7] Sharma, R R; Pawar, S J; Lad, S D; Mishra, G P; Netalkar, A S; Rege, S. Chapter 149 – Fungal Infections
of the Central Nervous System. In: Alfredo Quiñones-Hinojosa, editor. Surgical managament of
nervous system infections. Philadelphia: Saunders; 2012; 1691-1732.
[8] Koutsouras, G W; Ramos, R L; Martinez, L R. Role of microglia in fungal infections of the central
nervous system. Virulence, 2017 Aug 8, 705-718.
[9] Vu, K; Weksler, B; Romero, I; Couraud, P O; Gelli A. Immortalized human brain endothelial cell line
HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system
infection by Cryptococcus neoformans. Eukaryot. Cell, 2009 Sep 8, 1803-1807.
[10] Stie, J; Bruni, G; Fox, D. Surface-associated plasminogen binding of Cryptococcus neoformans
promotes extracellular matrix invasion. PLoS One, 2009 Jun 4, e5780.
[11] Charlier, C; Nielsen, K; Daou, S; Brigitte, M; Chretien, F; Dromer, F. Evidence of a role for monocytes
in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun, 2009 Oct 7, 120-127.
[12] Steinbach, W J. Antifungal agents in children. Pediatr. Clin. North Am., 2005 Jun 52, 895-915.
[13] Stockmann, C; Constance, J E; Roberts, J K; Olson, J; Doby, E H; Ampofo, K; Stiers, J; Spigarelli, M
G; Sherwin, CMT. Pharmacokinetics and pharmacodynamics of antifungals in children and their
clinical implications. Clin. Pharmacokinet., 2014 May 53, 429-454.
[14] Wirth, F; Ishida, K. Antifungal drugs: An updated review of central nervous system pharmacokinetics.
Mycoses, 2020 Aug 63, 1047-1059.
[15] Nagaraj, S; Manivannan, S; Narayan, S. Potent antifungal agents and use of nanocarriers to improve
delivery to the infected site: A systematic review. J. Basic Microbiol., 2021 Aug 61, 849-873.
[16] Xie, J; Shen, Z; Anraku, Y; Kataoka, K; Chen, X. Nanomaterial-based blood-brain-barrier (BBB)
crossing strategies. Biomaterials, 2019 Sep 224, 119491.
[17] Schwartz, S; Kontoyiannis, DP; Harrison, T; Ruhnke, M. Advances in the diagnosis and treatment of
fungal infections of the CNS. Lancet Neurol., 2018 Feb 17, 362-372.
[18] Ashley, E D. Antifungal Drugs: Special Problems Treating Central Nervous System Infections. J.
Fungi., 2019 Oct 5, 97.
[19] Kethireddy, S; Andes, D. CNS pharmacokinetics of antifungal agents. Expert Opin. Drug Metab.
Toxicol, 2007 Oct 3, 573-581.
[20] Nau, R; Sörgel, F; Eiffert, H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain
barrier for treatment of central nervous system infections. Clin. Microbiol. Rev., 2010 Oct 23, 858-883.
[21] Lutsar, I; Friedland, I R. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal
fluid. Clin. Pharmacokinet., 2000 Nov 39, 335-343.
[22] Snarr, B D; Drummond, R A; Lionakis, M S. It’s all in your head: antifungal immunity in the brain.
Curr Opin. Microbiol., 2020 Aug 58, 41-46.
[23] Felton, T; Troke, P F; Hope W W. Tissue penetration of antifungal agents. Clin. Microbiol. Rev., 2014
Jan 27, 68-88.
[24] Imbert, F; Jardin, M; Fernandez, C; Gantier, J C; Dromer, F; Baron, G; Mentre, F; Beijsterveldt, L;
Singlas, E; Gimenez, F., Effect of efflux inhibition on brain uptake of itraconazole in mice infected
with Cryptococcus neoformans. Drug Metab. Dispo., 2003 Mar 31, 319-325.
[25] Schwartz, S; Thiel, E. Update on the treatment of cerebral aspergillosis.
Ann. Hematol., 2004 Jan 83, 42-44.
[26] Reinwald, M; Uharek, L; Lampe, D; Grobosch, T; Thiel, E; Schwartz, S. Limited penetration of
posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary
aspergillosis. Bone marrow transplant., 2009 Feb 44, 269-270.
[27] Schwartz, S; Cornely, OA; Hamed, K; Marty, FM; Maertens, J; Rahav, G; Herbrecht, R; Heinz, WJ.,
Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous
system. Med. Mycol., 2020 Jun 58, 417-424.
[28] Schmitt-Hoffmann, A H; Kato, K; Townsend, R; Potchoiba, M J; Hope, WW; Andes, D; Spickermann,
J; Schneidkraut, M J., Tissue Distribution and Elimination of Isavuconazole following Single and
Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. Antimicrob. Agents Chemother.,
2017 Nov 61, e01292-17.
[29] Denning, D W. Echinocandin antifungal drugs. Lancet, 2003 Oct 362, 1142-1151.
[30] Eschenauer, G; Depestel, D D; Carver, P L. Comparison of echinocandin antifungals. Ther. Clin. Risk
Manag., 2007 Mar 3, 71-97.
[31] Dismukes, WE. Antifungal therapy: lessons learned over the past 27 years.
Clin. Infect. Dis., 2006 May 42, 1289-1296.
[32] Mesa-Arango, AC; Scorzoni, L; Zaragoza, O. It only takes one to do many jobs: Amphotericin B as
antifungal and immunomodulatory drug. Front. Microbiol., 2012 Aug 3, 286.
[33] Stott, K E; Hope, W. Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous
system. Expert Opin. Drug Metab. Toxicol., 2018 Jun 14, 803-815.
[34] Groll, A H; Giri, N; Petraitis, V; Petraitiene, R; Candelario, M; Bacher, JS; Piscitelli, S C; Walsh, T J.,
Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in Experimental
Candida albicans Infection of the Central Nervous System. J. Infect. Dis., 2000 Jul 182, 274-282.
[35] Lee, J W; Amantea, M A; Francis, P A; Navarro, E E; Bacher, J; Pizzo, P A; Walsh, T J.,
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in
rabbits. Antimicrob. Agents Chemother., 1994 Apr 38, 713-718.
[36] Wu, J Q; Shao, K; Wang, X; Wang, R Y; Cao, Y H; Yu, Y Q; Lou, J N; Chen, Y Q; Zhao, H Z; Zhang,
Q Q; Weng, X H; Jiang, C; Zhu, L P., In vitro and in vivo evidence for amphotericin B as a P glycoprotein substrate on the blood-brain barrier. Antimicrob. Agents Chemother., 2014 Aug 58, 4464-4469.
[37] Stevens, D A; Clemons, K V; Martinez, M; Chen, V. The brain, amphotericin B, and P-glycoprotein.
Antimicrob. Agents Chemother., 2015 Jan 59, 1386.
[38] Hamill, R J. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Drugs, 2013 Jun 73, 919-934.
[39] Bellmann, R; Smuszkiewicz, P. Pharmacokinetics of antifungal drugs: practical implications for
optimized treatment of patients. Infection, 2017 Jul 45, 737-779.
[40] Perfect, J R; Dismukes, W E; Dromer, F; Goldman, D L; Graybill, J R; Hamill, R J; Harrison, T S;
Larsen, R A; Lortholary, O; Nguyen, M H; Pappas, P G; Powderly, W G; Singh, N; Sobel, J D; Sorrell,
T C., Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the
infectious diseases society of america. Clin. Infect. Dis., 2010 Feb 50, 291-322.
[41] Vogelsinger, H; Weiler, S; Djanani, A; Kountchev, J; Bellmann-Weiler, R; Wiedermann, CJ; Bellmann,
R., Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin
B and amphotericin B colloidal dispersion. J. Antimicrob. Chemother., 2006 Apr 57, 1153-1160.
[42] Strenger, V; Meinitzer, A; Donnerer, J; Hofer, N; Dornbusch, H J; Wanz, U; Seidel, MG; Sperl, D;
Lackner, H; Schwinger, W; Sovinz, P; Benesch, M; Urban, C., Amphotericin B transfer to CSF
following intravenous administration of liposomal amphotericin B. J. Antimicrob. Chemother.,
2014 Jun 69, 2522-2526.
[43] Vermes, A. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity
and drug interactions. J. Antimicrob. Chemother., 2000 Aug 46, 171-179.
[44] Benson, J M; Nahata, M C. Clinical use of systemic antifungal agents.
Clin. Pharm., 1988 Jun 7, 424-438.
[45] Polak, A; Scholer, H J. Mode of action of 5-fluorocytosine and mechanisms of resistance.
Chemotherapy, 1975 21, 113-130.
[46] Nett, J E; Andes, D R. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical
Indications. Infect. Dis. Clin. North. Am., 2016 Mar 30, 51-83.
[47] Brouwer, A E; van Kan, H J M; Johnson, E; Rajanuwong, A; Teparrukkul, P; Wuthiekanun, V;
Chierakul, W; Day, N; Harrison, T S., Oral versus intravenous flucytosine in patients with human
immunodeficiency virus-associated cryptococcal meningitis. Antimicrob. Agents Chemother.,
2006 Dec 51, 1038-1042.
[48] Loyse, A; Dromer, F; Day, J; Lortholary, O; Harrison, TS. Flucytosine and cryptococcosis: time to
urgently address the worldwide accessibility of a 50-year-old antifungal. J. Antimicrob. Chemother.,
2013 Jun 68, 2435-2444.
[49] Zonios, D I; Bennett, J E. Update on azole antifungals. Semin. Respir. Crit. Care Med.,
2008 Apr 29, 198-210.
[50] Malani, A N; Kauffman, C A; Latham, R; Peglow, S; Ledtke, C S; Kerkering, T M; Kaufman, D H;
Triplett, P F; Wright, P W; Bloch, K C; McCotter, O; Toda, M; Jackson, B R; Pappas, P G; Chiller, T
M. Long-term Outcomes of Patients With Fungal Infections Associated With Contaminated
Methylprednisolone Injections. Open forum Infect. Dis., 2020 May 7, ofaa164.
[51] Galgiani, J N; Ampel, N M; Blair, J E; Catanzaro, A; Geertsma, F; Hoover, S E; Johnson, R H; Kusne,
S; Lisse, J; MacDonald, J D; Meyerson, S L; Raksin, P B; Siever, J; Stevens, D A; Sunenshine, R;
Theodore, N., 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the
Treatment of Coccidioidomycosis. Clin. Infect. Dis., 2016 Sep 63, e112-146.
[52] Johnson, R; Ho, J; Fowler, P; Heidari, A. Coccidioidal Meningitis: A Review on Diagnosis, Treatment,
and Management of Complications. Curr. Neurol. Neurosci. Rep., 2018 Mar 18, 19.
[53] Patterson, T F; Thompson, G R; Denning, D W; Fishman, J A; Hadley, S; Herbrecht, R; Kontoyiannis,
DP; Marr, K A; Morrison, V A; Nguyen, M H; Segal, B H; Steinbach, W J; Stevens, D A; Walsh, T J;
Young, J J H; Bennett, JE., Practice Guidelines for the Diagnosis and Management of Aspergillosis:
2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis., 2016 Aug 63, e1-60.
[54] Hoenigl, M; Krause, R. Antifungal therapy of aspergillosis of the central nervous system and
aspergillus endophthalmitis. Curr. Pharm. Des., 2013 19, 3648-3668.
[55] Coulter, L S; Bariola, J R. Current antifungal agents for treatment of central nervous system infections.
Curr. Fungal. Infect. Rep., 2014 8, 146-152.
[56] Fisher, K M; Montrief, T; Ramzy, M; Koyfman, A; Long, B. Cryptococcal meningitis: a review for
emergency clinicians. Intern. Emerg. Med., 2021 Jan 16, 1031-1042.
[57] Denora, N; Trapani, A; Laquintana, V; Lopedota, A; Trapani, G. Recent advances in medicinal
chemistry and pharmaceutical technology–strategies for drug delivery to the brain. Curr. Top Med.
Chem., 2009 9, 182-196.
[58] Lombardo, S M; Schneider, M; Türeli, A E; Türeli, NG. Key for crossing the BBB with nanoparticles:
the rational design. Beilstein J. Nanotechnol., 2020 Jun 11, 866-883.
[59] Zhou, Y; Peng, Z; Seven, E S; Leblanc, R M. Crossing the blood-brain barrier with nanoparticles. J.
Control. Release, 2018 Jan 270, 290-303.
[60] Gidwani, M; Singh, A V. Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and
in vitro models, opportunities and challenges. Curr. Pharm. Biotechnol., 2013 14, 1201-1212.
[61] Spadari, C C; Wirth, F; Lopes, L B; Ishida K. New Approaches for Cryptococcosis Treatment.
Microorganisms, 2020 Apr 8, 1-15.
[62] Niu, X; Chen, J; Gao, J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating
neurodegenerative diseases: Focus on recent advances. Asian J. Pharm. Sci., 2019 Sep 14, 480-496.
[63] Agrawal, M; Ajazuddin; Tripathi, D K; Saraf, S; Saraf, S; Antimisiaris, S G; Mourtas, S; Hammarlund Udenaes. M; Alexander. A. Recent advancements in liposomes targeting strategies to cross blood-brain
barrier (BBB) for the treatment of Alzheimer’s disease. J. Control. Release, 2017 Aug 260, 61-77.
[64] Saeedi, M; Eslamifar, M; Khezri, K; Dizaj, SM. Applications of nanotechnology in drug delivery to the
central nervous system. Biomed. Pharmacother., 2019 Mar 111, 666-675.
[65] Noble, G T; Stefanick, J F; Ashley, J D; Kiziltepe, T; Bilgicer, B. Ligand-targeted liposome design:
challenges and fundamental considerations. Trends Biotechnol., 2014 Jan 32, 32-45.
[66] Vieira, D B; Gamarra, L F. Getting into the brain: liposome-based strategies for effective drug delivery
across the blood-brain barrier. Int. J. Nanomedicine, 2016 Oct 11, 5381-5414.
[67] Lemke, A; Kiderlen, A F; Kayser, O. Amphotericin B. Appl. Microbiol. Biotechnol., 2005 Apr 68, 151-162.
[68] Grazziotin, L R; Moreira, L B; Ferreira, M A P. Comparative effectiveness and safety between
amphotericin B lipid formulations: A systematic review. Int. J. Technol. Assess Health Care,
2018 Jun 34, 343-351.
[69] Adler-moore, J P; Proffitt, R T. Development, Characterization, Efficacy and Mode of Action of
Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B. J. Liposome Res., 1993 3, 429-450.
[70] Fujii, G; Chang, J E; Coley, T; Steere, B. The formation of amphotericin B ion channels in lipid bilayers.
Biochemistry, 1997 Apr 36, 4959-4968.
[71] Adler-Moore, JP; Proffitt, RT. Amphotericin B lipid preparations: what are the differences? Clin.
Microbiol. Infect., 2008 May 14, 25-36.
[72] Janoff, AS; Boni, LT; Popescu, MC; Minchey, SR; Cullis, PR; Madden, TD; Taraschi, T; Gruner, SM;
Shyamsunder, E; Tate, MW. Unusual lipid structures selectively reduce the toxicity of amphotericin B.
Proc. Natl. Acad. Sci. U S A, 1988 Aug 85, 6122-6126.
[73] Moen, M D; Lyseng-Williamson, K A; Scott, L J. Liposomal amphotericin B: a review of its use as
empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Drugs, 2009 69, 361-392.
[74] Desai, JV; Urban, A; Swaim, DZ; Colton, B; Kibathi, LW; Ferrè, EMN; Stratton, P; Merideth, MA;
Hunsberger, S; Matkovits, T; Mannino, R; Holland, SM; Tramont, E; Lionakis, MS; Freeman, AF..,
Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal
Meningoencephalitis. mBio, 2019 May 10, e00724-19.
[75] Aigner, M; Lass-flörl, C. Encochleated Amphotericin B : Is the Oral Availability of Amphotericin B
Finally Reached? J. Fungi., 2020 May 6, 66.
[76] Zarif, L. Drug delivery by lipid cochleates. Methods Enzymol., 2005 391,314-329.
[77] Zarif, L; Graybill, J R; Perlin, D; Mannino, R J. Cochleates: New Lipid-Based Drug Delivery System.
J. Liposome Res., 2000 10, 523-538.
[78] Cuddihy, G; Wasan, E K; Di,Y; Wasan, K M. The Development of Oral Amphotericin B to Treat
Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized? Pharmaceutics, 2019
Feb 11, 1-16.
[79] Perlin, DS. Amphotericin B cochleates: a vehicle for oral delivery. Curr Opin Investig Drugs, 2004 Feb
5, 198-201.
[80] Liu, M; Chen, M; Yang, Z. Design of amphotericin B oral formulation for antifungal therapy.
Drug Deliv., 2017 Feb 24, 1-9.
[81] Lu, R; Hollingsworth, C; Qiu, J; Wang, A; Hughes, E; Xin, X; Konrath, K M; Elsegeiny, W; Park, Y
D; Atakulu, L; Craft, J C; Tramont, E C; Mannino, R; Williamson, P R., Efficacy of Oral Encochleated
Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis. MBio, 2019 May 10, e00724-19.
[82] Nair, K G S; Ramaiyan, V; Sukumaran, S K. Enhancement of drug permeability across blood brain
barrier using nanoparticles in meningitis. Inflammopharmacology, 2018 mar 26, 675-684.
[83] Wang, H; Xu, K; Liu, L; Tan, JPK; Chen, Y; Li, Y; Fan, W; Wei, Z; Sheng, J; Yang, Y; Li, L., The
efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus
neoformans for the treatment of meningitis. Biomaterials, 2010 Apr 31, 2874-2881.
[84] Xu, N; Gu, J; Zhu, Y; Wen, H; Ren, Q; Chen, J. Efficacy of intravenous amphotericin B polybutylcyanoacrylate
nanoparticles against cryptococcal meningitis in mice. Int. J. Nanomedicine, 2011 Apr 6, 905-913.
[85] Ren, T; Xu, N; Cao, C; Yuan, W; Yu, X; Chen, J; Ren, J. Preparation and therapeutic efficacy of
polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles.
J. Biomater. Sci. Polym. Ed., 2009 20, 1369-1380.
[86] Lim, W M; Rajinikanth, P S; Mallikarjun, C; Kang, Y B. Formulation and delivery of itraconazole to
the brain using a nanolipid carrier system. Int. J. Nanomedicine, 2014 May 9, 2117-2126.
[87] Yukuyama, M N; Ishida, K; Araujo, GLB; Spadari, C C; Souza A; Löbenberg, R; Henostroza, M A B;
Folchini, B R; Peroni, C M; Peters, M C C; Oliveira, I F; Miyagi, M Y S; Bou-Chacra, N A., Rational
design of oral flubendazole-loaded nanoemulsion for brain delivery in cryptococcosis. Colloids
Surfaces A Physicochem Eng Asp, 2021 Dec 630, 127631.
[88] Kreuter, J. Nanoparticulate systems for brain delivery of drugs.
Adv. Drug. Deliv. Rev., 2012 Dec 64, 213-222.
[89] Ćurić, A; Möschwitzer, J P; Fricker, G. Development and characterization of novel highly-loaded
itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles. Eur. J. Pharm. Biopharm., 2017 May
114,175-185.
[90] Thammasit, P; Tharinjaroen, C S; Tragoolpua, Y; Rickerts, V; Georgieva, R; Bäumler H; Tragoolpua,
K., Targeted Propolis-Loaded Poly (Butyl) Cyanoacrylate Nanoparticles: An Alternative Drug Delivery
Tool for the Treatment of Cryptococcal Meningitis. Front. Pharmacol., 2021 Aug 12, 723727.
[91] Demeule, M; Régina, A; Ché, C; Poirier, J; Nguyen, T; Gabathuler, R; Castaigne, J P; Be´ liveau, R.,
Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp.
Ther., 2008 Mar 324, 1064-1072.
[92] Shao, K; Huang, R; Li, J; Han, L; Ye, L; Lou, J; Jiang, C., Angiopep-2 modified PE-PEG based
polymeric micelles for amphotericin B delivery targeted to the brain.
J. Control. Release, 2010 Oct 147, 118-126.
[93] Shao, K; Wu, J; Chen, Z; Huang, S; Li, J; Ye, L; Lou, J; Zhu, L; Jiang, C., A brain-vectored angiopep 2 based polymeric
micelles for the treatment of intracranial fungal infection. Biomaterials, 2012 Oct 33, 6898-6907.
[94] Chen, W; Zhan, C; Gu, B; Meng, Q; Wang, H; Lu, W; Hou, H., Targeted brain delivery of itraconazole
via RVG29 anchored nanoparticles. J. Drug Target, 2011 Apr 19, 228-234.
[95] Zhang, Q L; Fu, B M; Zhang, Z J. Borneol, a novel agent that improves central nervous system drug
delivery by enhancing blood-brain barrier permeability. Drug Deliv., 2017 Jul 24, 1037-1044.
[96] Zhang, S; Asghar, S; Yang, L; Hu, Z; Chen, Z; Shao, F; Xiao, W., Borneol and poly (ethylene glycol)
dual modified BSA nanoparticles as an itraconazole vehicle for brain targeting.
Int J Pharm, 2020 Feb 575,119002.
[97] Tang, X; Liang, Y; Zhu, Y; Xie, C; Yao, A; Chen, L; Jiang, Q; Liu, T; Wang, X; Qian, Y; Wei, J; Ni,
W; Dai, J; Jiang, Z; Hou, W., Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG
nanoparticles cure Candidal meningitis and reduce drug toxicity.
Int. J. Nanomedicine, 2015 Oct 10, 6227-6241.
[98] Gadekar, V; Borade, Y; Kannaujia, S; Rajpoot, K; Anup, N; Tambe, V; Kalia, K; Tekade, RK.,
Nanomedicines accessible in the market for clinical interventions.
J. Control. Release, 2021 Feb 330, 372-397.
[99] Zeeshan, M. Nanopharmaceuticals: A Boon to the Brain-Targeted Drug Delivery. In: Mukhtar M,
editor. Pharmaceutical Formulation Design. London: IntechOpen, 2020, 1-21.
[100] Junghanns, JUAH; Müller, R H. Nanocrystal technology, drug delivery and clinical applications. Int.
J. Nanomedicine, 2008 Sep 3, 295-309.
[101] Teixeira, M I; Lopes, C M; Amaral, M H; Costa, P C. Current insights on lipid nanocarrier-assisted
drug delivery in the treatment of neurodegenerative diseases. Eur. J. Pharm. Biopharm.,
2020 Apr 149,192-217.
[102] Varkony, H; Weinstein, V; Klinger, E; Sterling, J; Cooperman, H; Komlosh, T; Ladkani, D; Schwartz,
R., The glatiramoid class of immunomodulator drugs.
Expert Opin. Pharmacother., 2009 Feb 10, 657-668.
[103] Nance, E; Pun, S H; Saigal, R; Sellers, D L. Drug delivery to the central nervous system.
Nat Rev Mater, 2021 Dec, 1-18.
[104] Beier, CP; Schmid, C; Gorlia, T; Kleinletzenberger, C; Beier, D; Grauer, O; Steinbrecher, A;
Hirschmann, B; Brawanski, A; Dietmaier, C; Jauch-Worley, T; Kölbl, O; Pietsch, T; Proescholdt, M;
Rümmele, P; Muigg, A; Stockhammer, G; Hegi, M; Bogdahn, U; Hau, P., RNOP-09: pegylated
liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed
glioblastoma–a phase II study. BMC Cancer, 2009 Sep 9, 308.
[105] Cheung, K L; Robertson, J F. Preoperative hormone therapy trials for breast cancer.
Breast, 2001 Feb 10, 1-5.
[106] Kim, S S; Harford, J B; Moghe, M; Slaughter, T; Doherty, C; Chang, E H. A tumor-targeting
nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1
immunotherapy in mouse models of glioblastoma. Int. J. cancer, 2019 Nov 145, 2535-2546.
[107] Metselaar, J M; Lammers, T. Challenges in nanomedicine clinical translation. Drug. Deliv. Transl. Res.,
2020 Mar 10, 721-725.
[108] Sercombe, L; Veerati, T; Moheimani, F; Wu, S Y; Sood, A K; Hua, S. Advances and Challenges of
Liposome Assisted Drug Delivery. Front. Pharmacol., 2015 Dec 6, 286.
[109] Soliman, G M. Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements
and challenges. Int. J. Pharm., 2017 May 523, 15-32.

Category:

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!

See some of our Authors and Editors